Skip to main
GPCR
GPCR logo

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc has demonstrated significant positive momentum as its stock surged over 25% following the promising ACHIEVE-1 results for orforglipron. The drug candidate has shown improved gastrointestinal tolerability with a slower titration strategy in Phase 3 trials, mitigating previous concerns regarding side effects while enhancing both liver safety and cardiovascular profiles. Additionally, the performance metrics suggest that orforglipron's development aligns with the company's goal of addressing chronic diseases with unmet medical needs, reinforcing the potential for strong future financial performance.

Bears say

Structure Therapeutics Inc. faces significant financial challenges, evidenced by a trading valuation of approximately $410 million in enterprise value and a 20% year-to-date decline in shares, indicating market skepticism about its prospects. The company is expected to incur ongoing net losses at least until commercialization and likely through the early launch phase, raising concerns regarding its financial sustainability. Additionally, despite its advancements in drug development, the company may need to seek commercial partnerships to effectively penetrate the lucrative diabetes and obesity markets amid its preclinical pipeline uncertainties.

GPCR has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 7 analysts, GPCR has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.